Published in Ann Am Thorac Soc on January 01, 2015
A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care (1996) 70.87
Standardisation of spirometry. Eur Respir J (2005) 48.20
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis (1992) 15.92
The St George's Respiratory Questionnaire. Respir Med (1991) 8.49
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes (2005) 2.42
Assessment of health-related quality of life in patients with interstitial lung disease. Chest (1999) 2.21
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax (1992) 2.11
Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 2.01
Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J (2001) 1.50
Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes (2006) 1.49
Measuring health-related quality of life in older patient populations: a review of current approaches. Pharmacoeconomics (2005) 1.44
Aging and perceived health status. J Gerontol (1983) 1.36
Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease. Respir Med (2000) 1.23
Characterization of older adults who attribute functional decrements to "old age". J Am Geriatr Soc (1996) 1.12
Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respir Med (2007) 1.10
Influence of social desirability on age differences in self-reports of mood and personality. J Pers (2011) 1.06
Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish Study. Int J Chron Obstruct Pulmon Dis (2008) 0.99
Gender influences Health-Related Quality of Life in IPF. Respir Med (2009) 0.92
Measuring the quality of life of the elderly in health promotion intervention clinical trials. Public Health Rep (1992) 0.90
Effect of aging on the perception of resistive ventilatory loads. Am Rev Respir Dis (1982) 0.89
Effect of aging on respiratory sensations produced by elastic loads. J Appl Physiol Respir Environ Exerc Physiol (1981) 0.87
Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. Chest (2012) 0.86
Effects of aging on sensation of dyspnea and health-related quality of life in elderly asthmatics. Aging Clin Exp Res (2005) 0.83
Effects of aging on respiratory load compensation and dyspnea sensation. Am Rev Respir Dis (1993) 0.77
Effects of aging on sensation of respiratory force and displacement. J Appl Physiol Respir Environ Exerc Physiol (1983) 0.77
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med (2004) 17.08
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med (2005) 8.86
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med (2009) 5.90
Pneumocystis pneumonia. N Engl J Med (2004) 5.86
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med (2011) 4.75
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med (2007) 4.40
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med (2009) 4.05
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med (2008) 3.94
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Pneumocystis pneumonia in patients treated with rituximab. Chest (2013) 3.48
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA (2012) 3.40
Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med (2011) 3.33
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 3.24
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Diffuse alveolar hemorrhage. Chest (2010) 2.90
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 2.82
Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med (2007) 2.80
Spirometry utilization for COPD: how do we measure up? Chest (2007) 2.77
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS One (2008) 2.67
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med (2009) 2.63
Maternal vitamin A supplementation and lung function in offspring. N Engl J Med (2010) 2.61
A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nat Immunol (2013) 2.60
Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med (2010) 2.60
Calcium deposition with or without bone formation in the lung. Am J Respir Crit Care Med (2002) 2.57
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol (2007) 2.50
Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A (2004) 2.42
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med (2003) 2.35
MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med (2013) 2.31
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 2.20
Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2007) 2.19
Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest (2005) 2.15
Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax (2012) 2.15
The relationship between pulmonary emphysema and kidney function in smokers. Chest (2012) 2.13
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
Automated lung segmentation in X-ray computed tomography: development and evaluation of a heuristic threshold-based scheme. Acad Radiol (2003) 2.10
Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J (2005) 2.09
Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.09
Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs (2004) 2.05
Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax (2007) 2.05
Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med (2004) 2.05
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04
Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med (2003) 2.03
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax (2013) 1.99
Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.98
Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis (2002) 1.98
Significance of the microbiome in obstructive lung disease. Thorax (2012) 1.97
Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med (2007) 1.94
Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.94
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med (2007) 1.94
Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol (2005) 1.93
The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS (2013) 1.92
Body mass index and the risk of COPD. Chest (2002) 1.91
An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.91